238 related articles for article (PubMed ID: 33141886)
1. Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura.
Lu R; Sui J; Zheng XL
Blood Adv; 2020 Nov; 4(21):5378-5388. PubMed ID: 33141886
[TBL] [Abstract][Full Text] [Related]
2. Plasma Levels of Big Endothelin-1 Are Associated with Renal Insufficiency and In-Hospital Mortality of Immune Thrombotic Thrombocytopenic Purpura.
Lu R; Zheng XL
Thromb Haemost; 2022 Mar; 122(3):344-352. PubMed ID: 33984867
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of S100A8/A9, histone/DNA complexes, and cell-free DNA predict adverse outcomes of immune thrombotic thrombocytopenic purpura.
Sui J; Lu R; Halkidis K; Kocher NK; Cao W; Marques MB; Zheng XL
J Thromb Haemost; 2021 Feb; 19(2):370-379. PubMed ID: 33188723
[TBL] [Abstract][Full Text] [Related]
4. The standard of care for immune thrombotic thrombocytopenic purpura today.
Zheng XL
J Thromb Haemost; 2021 Aug; 19(8):1864-1871. PubMed ID: 34060225
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.
Sui J; Cao W; Halkidis K; Abdelgawwad MS; Kocher NK; Guillory B; Williams LA; Gangaraju R; Marques MB; Zheng XL
Blood Adv; 2019 Dec; 3(24):4177-4186. PubMed ID: 31856267
[TBL] [Abstract][Full Text] [Related]
6. Immune-mediated thrombotic thrombocytopenic purpura in patients with and without systemic lupus erythematosus: a retrospective study.
Yue C; Su J; Fan X; Song L; Jiang W; Xia J; Shi T; Zhang X; Li X
Orphanet J Rare Dis; 2020 Aug; 15(1):225. PubMed ID: 32859237
[TBL] [Abstract][Full Text] [Related]
7. Pregnancy and non-pregnancy related immune thrombotic thrombocytopenic purpura in women of reproductive age.
Rottenstreich A; Dor S; Keren-Politansky A; Sarig G; Nadir Y; Ellis M; Spectre G; Kirgner I; Pikovsky O; Arad A; Dann EJ; Kalish Y
J Thromb Thrombolysis; 2021 Jan; 51(1):187-193. PubMed ID: 32388825
[TBL] [Abstract][Full Text] [Related]
8. Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigen.
Dekimpe C; Roose E; Tersteeg C; Joly BS; Dewaele A; Horta S; Pareyn I; Vandenbulcke A; Deckmyn H; Feys HB; Tellier E; Kaplanski G; Scully M; Coppo P; De Meyer SF; Veyradier A; Vanhoorelbeke K
J Thromb Haemost; 2020 Apr; 18(4):985-990. PubMed ID: 31989742
[TBL] [Abstract][Full Text] [Related]
9. [Endothelial dysfunction in thrombotic thrombocytopenic purpura: therapeutic perspectives].
Prevel R; Roubaud-Baudron C; Tellier E; Le Besnerais M; Kaplanski G; Veyradier A; Benhamou Y; Coppo P;
Rev Med Interne; 2021 Mar; 42(3):202-209. PubMed ID: 33455838
[TBL] [Abstract][Full Text] [Related]
10. Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.
Roose E; Schelpe AS; Tellier E; Sinkovits G; Joly BS; Dekimpe C; Kaplanski G; Le Besnerais M; Mancini I; Falter T; Von Auer C; Feys HB; Reti M; Rossmann H; Vandenbulcke A; Pareyn I; Voorberg J; Greinacher A; Benhamou Y; Deckmyn H; Fijnheer R; Prohászka Z; Peyvandi F; Lämmle B; Coppo P; De Meyer SF; Veyradier A; Vanhoorelbeke K
Blood; 2020 Jul; 136(3):353-361. PubMed ID: 32356859
[TBL] [Abstract][Full Text] [Related]
11. Taking Empiricism out of Immune Thrombotic Thrombocytopenic Purpura: Current and Future Treatment Strategies.
Mazepa MA; Park YA; Raval JS
Transfus Med Rev; 2019 Oct; 33(4):248-255. PubMed ID: 31645275
[TBL] [Abstract][Full Text] [Related]
12. Effects of convalescent plasma infusion on the ADAMTS13-von Willebrand factor axis and endothelial integrity in patients with severe and critical COVID-19.
Zhang Q; Ye Z; McGowan P; Jurief C; Ly A; Bignotti A; Yada N; Zheng XL
Res Pract Thromb Haemost; 2023 Jan; 7(1):100010. PubMed ID: 36531671
[TBL] [Abstract][Full Text] [Related]
13. Blood-brain barrier permeability in survivors of immune-mediated thrombotic thrombocytopenic purpura: a pilot study.
Huang SS; Pavenski K; Lee TY; Jurkiewicz MT; Bharatha A; Thiessen JD; St Lawrence K; Théberge J; Mandzia J; Barth D; Licht C; Patriquin CJ
Blood Adv; 2021 Oct; 5(20):4211-4218. PubMed ID: 34521110
[TBL] [Abstract][Full Text] [Related]
14. How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge.
Akwaa F; Antun A; Cataland SR
Blood; 2022 Aug; 140(5):438-444. PubMed ID: 35667044
[TBL] [Abstract][Full Text] [Related]
15. Daratumumab for immune thrombotic thrombocytopenic purpura.
van den Berg J; Kremer Hovinga JA; Pfleger C; Hegemann I; Stehle G; Holbro A; Studt JD
Blood Adv; 2022 Feb; 6(3):993-997. PubMed ID: 34551063
[TBL] [Abstract][Full Text] [Related]
16. Survival after acute episodes of immune-mediated thrombotic thrombocytopenic purpura (iTTP) - cognitive functioning and health-related quality of life impact: a descriptive cross-sectional survey of adults living with iTTP in the United Kingdom.
Holmes S; Podger L; Bottomley C; Rzepa E; Bailey KMA; Chandler F
Hematology; 2021 Dec; 26(1):465-472. PubMed ID: 34238132
[TBL] [Abstract][Full Text] [Related]
17. Hemostatic Profile and Serological Response of Patients with Immune Thrombotic Thrombocytopenic Purpura after Receiving BNT162b2 Vaccine: A Prospective Study.
Schieppati F; Russo L; Gamba S; Galimberti E; Giaccherini C; Tartari CJ; Bolognini S; Verzeroli C; Ticozzi C; Barcella L; Marchetti M; Falanga A
Thromb Haemost; 2023 Oct; 123(10):945-954. PubMed ID: 37172940
[TBL] [Abstract][Full Text] [Related]
18. Immune thrombotic thrombocytopenic purpura: Spotlight on long-term outcomes and survivorship.
Selvakumar S; Liu A; Chaturvedi S
Front Med (Lausanne); 2023; 10():1137019. PubMed ID: 36926315
[TBL] [Abstract][Full Text] [Related]
19. Identification of Biomarkers in Patients with Thrombotic Thrombocytopenic Purpura Presenting with Large and Small Ischemic Stroke.
Lin C; Memon R; Sui J; Zheng XL
Cerebrovasc Dis Extra; 2021; 11(1):29-36. PubMed ID: 33601375
[TBL] [Abstract][Full Text] [Related]
20. Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival.
Prevel R; Roubaud-Baudron C; Gourlain S; Jamme M; Peres K; Benhamou Y; Galicier L; Azoulay E; Poullin P; Provôt F; Maury E; Presne C; Hamidou M; Saheb S; Wynckel A; Servais A; Girault S; Delmas Y; Chatelet V; Augusto JF; Mousson C; Perez P; Halimi JM; Kanouni T; Lautrette A; Charvet-Rumpler A; Deligny C; Chauveau D; Veyradier A; Coppo P
Blood; 2019 Dec; 134(24):2209-2217. PubMed ID: 31530564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
